Chimeric Therapeutics Limited (CHM) stands as a clinical-stage cell therapy company at the forefront of Australia's advancements in cell therapy. Dedicated to realising the potential of cell therapy for a broader spectrum of cancer patients, Chimeric is led by a team of pioneers and experts in the field. Their focus spans from initial discovery through to the development and eventual commercialisation of innovative cell therapies. Presently, Chimeric boasts a diverse portfolio encompassing two autologous CAR T cell therapies alongside allogeneic NK cell therapies, promising new avenues in the fight against cancer.